International Journal of Experimental Pathology
(company limited by guarantee)
Report and Financial Statements
for the year ended 31 December 2022
Charity No. 231407
Company No. 355858

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Report and Financial Statements for the year ended 31 December 2022
Contents
Page
Trustees, report
Independent examiner's report
Statement of financial activities
Balance sheet
Notes to the financial Statements
io

INTERNATIONAL JOURNAL OF EXPERIMETrrfAL PATHOLOGY
Page I
Trustses, report (incorporating the directors, report) for
the year ended 31 December 2022
The T￿Stees, who are also directors of the charity for the purposes of the Companies Ac(, present
their annual report and accounts for the year ended 31 DecemE￿[ 2022. The accounts comply with
th¢ Charities Act 201 I, the Companies Act 2(M￿, the Memorandum and Articles of Association and
Accounting and Reporting by Ch￿illes: sta￿ment of Recommended Pracuce applicable to chariCi¢S
preparing their accouThts in a￿OrdanCe with the Financial Reporting Standard applicable in the UK
and Republic of Ireland (FRS 102) October 2019.
Reference and Administrative infonnation
Company Number
355858 (England and Wales)
R¢gistered Charily No.
231407
Directors and Members
of the Council (r￿steeS)
Professor l Lauder - President
Professor M Alison- Vice President
Profe550r G Murphy- Secretary
Professor J Shaw
Professor R Goldin
Editor
Professor D R Katz
Registered Office
28 Pheasants Way
Rickniansworth
Hertfordshire
WD3 7ES
Bankers
CAF Bank Limi(
25 Kings Hill Avenue
Kings Hill
Wesi Malling
Kent
ME19 4JQ
Investment Managers
Canaccord GeThuity Wealth Management
Slip House. Princes Drive
Worcester
WRI 2AB
Independent Examiner
Paul HaTris
Paul Harris & Co Limited
59 West End
Rednjth
Cornwall
TR15 2SQ

INTERNATIONAL JOURNAL OF EXPERDAENTAL PATHOLOGY
Page 2
Trustees, report (incorporating the directors, report) for
the year ended 31 December 2022 (continued)
Strncture, Governance and Management
Governing document
The charity is constituted as a cornpany limited by guardntee and is therefore governed by a
Memorandum and Articles of ASs(￿lation. The liability of m¢mbers in the evenl of a winding up is
limited to £10. Control of the company is vested in the Board of Trustees.
Recruitment and appointment of Trustees
The Trusie¢s are also directors of the company for the purposes of the Companies Act and are
known as Members of the Council under the company's Articles of Asswiation. Und¢r the
requirements of the Memorandum and Articles of A$S￿lation. one frfth of the MeM￿rS of the
Council must retire ai each Annual GeTheral Meeting. these being the members who have been in
office the longest. The retiring members ar¢ ¢ligible for re<leciion
In accordance with th¢ Articles of Association. Professor G Murphy retires and offers herself for re-
election.
All Trustees have expertise in the field of experimental pathology and when Trustees retire. they are
replaced by persons with similar expertise. Th¢ Board has the tM)wer to appoint additional Trustees
as it considers fil to do so.
All Trustees give of their time freely and no Trustee received remuneration in the year. Trustees,
rcimbursed rravelling expenses are shown in Not¢ 5 to the accounts.
Objectives and activities
The charity's object and its prillcipal activity continues to be that of the publication of the Journal.
Our policy is to publish research into the cause, diagnosis and cure of disease in man. and any
Profits from such publication are used to promote research in this field. The Trustees confirni that
they have considered the Charity Commission's public ￿nefit guidancc when reviewing the aims
and objectives. MB PhD Fellowship awards are made to research instiiutions io fund nominated
students whose area of interest furthers the objects of the charity. Sponsorship of an annual leciure
and prizes are provided to the British Society for Matrix Biology.
The type of material that is published. including FA)th primary research papers xnd reviews, is
subject to peer review and is monitored by an Editorial Board, composed of an iniernational group
of ex￿rtS in the field of experimental pathology, which meets three times each year.
The Trnstees meet as a Board of Directors to detennine the general policy of the Journal. which has
remained unchanged.

INTERNATIONAL JOURNAL OF EXPERImETr￿AL PATHOLOGY
Page 3
Trust￿, report (incorporating the directors, report) for the year ended 31 December 2022
(continued)
Achievements and perforniance
Journal activities during 2022 continued onwards from p￿VIouS years. with the smooth and
efficieni support of the Editorial O￿lee (Ms Biljana Nikolic), which is the major Journal assec.
During 2022 the impact of Covid-19 continued to be felL The advances in informaiion technology,
and the much wider prevalence of imn]ediate response methods. impact inevitably on publishing.
Some of the pandemic effects have persisted, and processes thai weie waived during that period
have not been reinstated. Competition in the journal markei remains intense with yet further
increased penetration of paperniills. Unfortunately, the image softwar¢ and IP address monitoring
that were proposed by Wiley- Blackwell were not introduced during 2022. Meantitne. referee
recruitment (and review solicitations) continue to be more difficuli than previously. One of the
problems (indeed hallnlarks!) of "non-paperniill" papers is that the language and grammar is
substandard. which brings its own problems.
Links with the British Society for Matrix Biology (BSMB) continued 10 be excellent, Profs
Piisillides and Midwood have worked with the Editor to ensure Ihat these are maintained and
extended.
New different fonns of support for research in pathology have been initiated. The prize award for
the besi MBPHD thesis at UCL was noi funded by the Journal in 2022 bui this will be initiated in
2023 in memory of Prof Neville Woolf. Fornier UCL MBPhD students have organised oppormnities
for undewaduate medical students to do research during the summer vacation. This Rani Rawji
Scholarship scheme attfdcied 80 applicants for 15 places in 2022, three of which were supported by
the Journal.
During 2022 501 (2021.456) manuscripts were handled of which 455 (2021: 415) were new
submissions. This represents an increase of 45 papers (2021.. 96) when there were already 227 more
than in 2019. 310 (2021: 281) manuscripts were handled to completion during 2022. Acceptance
rate was 7.1% for 2022 overall (2021: 7%). 92.9% (2021". 393) were rejected. For all manuscripts
with fjnal decisions from those submitted during 2022 5.8% were accepted and 56.1 % were
rejected. For all revised tnanuscripts submitied during 2022 60.8% were accepied and 2 (4.3%)
were rejecied. Of the revie￿, articles (only one of which was commissioned) 2 (12.5%) were
accepted. 28 papers were published (including abstracts) and the 10(al number of pages was 284.
The Journal is graleful for all the efforts made by referees during the year. 712 r¢viewers were
invi(¢d (2021: 1.158) and 230 (2021: 303) reviews were received. The median time to receipt of
reviews 15 14 days.
The Journal is accessible lo 2,514 SUbS￿lber5 via the Wiley All Journals Licence, representing
4,145 siies in 41 countries. Transfonnational agreements have been agreed with 2.048 institutions.
Overall 7.091 institU¢ions (2021: 7.182) have ready access. There is major emphasis on exlending
open access - this approach leads to 3.2x downloads. 1.5 x more citations and 2.7 x higher altme(ric
scores. Iliileys have also signed the Declaration on Research Assessment which aims to move from
journal based metric5 to article based metrics. During 2022 philanthropic initiaiives extended low-
cost or free access to current conteni to 4.304 instirutions froffl 72 counties. developing world
institutions

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Pag¢ 4
Trustees, report (incorporating the directors, report) for the year ended 31 December 2022
{continued)
Achievements and perfonnance (Contlnued)
The review article published during 2022 was..
Role of extracellular matrix
roteo
cans in immune cell recrnitment Anna L. Gray, Nabina Pun.
Atnanda J. L. Ridley, Douglas P. Dyer Int J Exp Pathol. 2022: 103.2 3443 (published online Jan 25
2022).
Download access to articles durkng 2022 was >4(K),(MX). Of these 22% were from Chin4 16% were
from the USA and 7% from Ihe UK. 33% downloads were classified as "other- in origin. The iotal
download access numbers reflect not only Wiley Online Library but also other sources such as Pub-
Med.
Altmetric scores (which reflec( wider media access) were also recorded and there were 320
mentions. The most frequeni mention oierall was of an original paper from Ochiai E ei al entitled
'Inhala(i
n of stach bo
s chartaDJrn causes
ulffton
arterial h
rtension in mice" whicb
ared in 89.201-8 2008.
The two y&4r Impact Factor announced in 2022 w&$ 2.793. The 10 most frequendy cited articles
contributing to the 2022 Impact Factor were:
Masson-meyers D et al Experimental mcdels and Meth￿IS for cutaneous wound healing
ass¢s5ment. 101.21-37 2020
Yamada K et al Extfdcellular matTiX dynamics in cell n]igration. invasion and tissue morphogenesis
100.144-52 2019
ADAMTS-5: A difficult teenager turning 20 101.420 2020
c0-exp￿Ssion of TLR-9 and MMP-13 is a$S￿lated with the degree of tumour diff¢r¢ntiation in
prostate cancer. 100'.123-32 2019
Non-inferiority of microencapsulated mesenchymal stem cells to free cells in cardiac repair after
My0ca￿la] infarction". A rduonale for using paracrine factor(s) instead of cells 100'.102-13 2019
The effects of intravitreal H2S applicauon on apoptosis in the retina and cornea in experimental
glaucoma model 100..330-6 2019
Carboxypeptidase A4 promotes proliferalion and stem cell characteristics of hepatocellular
carcinoma IW'.133-8 2019
Identificacion of funclionai long non<(Kling RNAS in gastric cancer by bioinfonrlatics analysis
101.96-105 2020
Long non-coding RNA GAS5 overexpression inhibits M2-like polarization of tumour-associaied
macrophages in SMCC-7721 cells by promoting iyfEN expression 101.215-22 2020
Resverdtrol attenuates cerebral ischaemia reperfusion injury via m¢yJulating MItt￿h0ndrAal
dynamics homeostasis and acuvating AMPK-Mfn I pathway l(Y)..33749 2019
Of these three out of ten were r¢views.
The Altmetric scores (reflecting wider n￿dia interest) for the year 2022 were:
Role of extracellUl￿ matrix proteoglycans in immune cell recruitment 103.3443 2022- 16
Skin fibr(isis associated with keloid, scleroderma and Jorge Lobo's disease Ilacaziosis): An imtnune-
hiscochemical study 103.23444 2022- 2
High level of FHL2 exacerbates the outcome of non-small cell lung cancer (NSCLC) patients and
the malignant phenotype in NSCLC cells 103.90-1012022 - 2
Autoantibodies dir¢cted against glutsmaie decarboxylase interfere with glucose-stimulated insulin

RNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Page 5
Thiste￿, report (inCOTporatlng the directors. report) for the year ended 31 December 2022
(continued)
Achievements and performance (continued)
secretion in dispersed rat islets 103.40-8 2022 - 2
ReTnifentanil reduces the proliferation. migration and invasion of HCC cell5 via IncRNA
NBR21miR-650rriMP3 axis 103.44-53 2022 - 1
Two sets of abstracts were published from tbe British Societ for Mairix Biolo
BSMB
meetin
s. These were from ihe BSMB Autumn 2021 Meeiin
"Exrracellular Matrix and Rare
Disease". Inl J Exp Pathol. 2022: 103..1 AI-A14 (published online Jan 25, 2022). and from the
Spring 2022 Meeting: "Interactions between Lipids l Derivatives and the Extracellular Matrix" Int
J Exp Pathol. 2022.. 103.6 AI-A8 (published online Nov 15. 2022).
Three prizes were awarded at ¢acb of the British S(Kiety for Matrix Biology meetings in Autumn
2021 and Spring 2022.
Two MBPhD Lachmann Fellowships continued:
Cambridge: Alex Fleet who is working on a project entitled 'thanges in the Oligodendrocyte
Progenitor Cell Nuclear Lamina during Ageing"
UCL.. Deborah Oluwadamilola Alawode who is working on a project enlitled "Developing Novel
Super Sensitive Fluid Biomark¢r Assays in Neurodegen¢ra(ive Dise&ses" supervised by Prof Henrik
Zeiterberg (primary) and Dr Amanda Heslegrnve (subsidiary).
In addition:
UCL: Bridging support for one year was provided for Vaishnavi SabarigiTivasan who is working on
a project entitled 'X)rigins and evolution of telralogy of Fallot.. Using Synchrotron-based
Hierarchical X-ray Phase-contrdst Tomography to link micro-structurdl anatomy to development
and treatment of dÉsease" supervised by Prof Andrew Cook.
Financial review
The statement of financial aclivities on page 8 shows the fjnancial iesulls of the year's activities.
The balance sheet on page 9 shows the posilion at the end. There was a small increase in nel
revenue from the Journal. Inyesunent income increased by 25%. The charity continued lis SUPPOrt
for the Fellowship awards to University of Cambridge and University College IA)ndon, the annual
Fell Muir lecture and British s￿IetY of Matrix Biology pri7Es. A new one year Fellowship award
was agreed for a Universiry College London student. Funding was also provided for five students
from the Rani Rawji Foundation. The investment portfolio perfornied in line with expectations
based on global equity markets. with net unrealised losses of £173.182 over the year. The decrease
in valu¢ of investments does not impact on the charity's funding pattern or comtnitments. as income
and reserves are sutricient to maintain funding for the foreseeable fijture. Overall. the twstees
consider that Ihe charity is in a srrong position io continue its work.

I1￿ERNATIONAL JOURNALOF EXPERtMFNfAL PATHOLOGY
Page 6
the yeAr ended 31 December 2022 (C￿￿￿lled)
Investment pollcy
Under d* Memorath aud Articles of Association. the charity the power to make any
inv¢stm¢nt whith th¢ Trustees se¢ fiL The Tntstees. policy for investing funds is to generate both
incon* and capitsl growth and tbe Investhia￿ ￿￿0110 is Trgularly reviewed for this purpo
Ethical issues are given due coL8idetation when investmetrt decisions are rn￿¢. Funds not ￿qUIred
for immth use are inv¢sted in highu interest pying xcouTht& The Trustees consider the tetum
on investDMts in the year to be satisfxtory.
Resuves are mainrnined at levels which are necessary to support the continuation of the pub]ication
of the Journal and the Fellowships awarded The balance on general unrestricted resezyes at the year
end was £1.119.243.
Statemtht of trustees, rU￿n￿bIlItIeS
The Tn￿ are required by law to prepate financial sl*ments for exh financial year wbich give
a true and fair view of the rinp￿￿1al activities of the charity and of its firlancial position at the end of
' sel#t suitable accounting ￿111¢1¢5 and apply them consistently;
' make judgements and estimates that are reasonable and prudent:
• state wbether the policies adoved are in accordance with the Companies Act 2(XY6 and with
applicable accounting standard5 and sLitements of recommended pwtsce, subjett to any
material departur￿ disclosed and explained in the financial statements. and
. prepare the financial stateTh￿ts on a going concern bAsis unless it is Inappr￿late to assum¢
that the clwity will continue in operntion.
The Trustees are responsible for keeping proper accounting records which disclose with reasonable
accuracy at any time the financial position of the charity and enable thein to ensure that the
fin￿￿181 staten￿ts comply with the Cornpanies Act 2(￿. They are also responsible for
safeguarding the assets of the charity and hence for taking reasonable steps for the ￿ention and
d¢￿tion of fraud aud other inEgulatilies.
This report Iw been prepared in I￿ordall￿ with the provisions in Paff 15 of the Companies Act
2(M)6 applicable io companies subject ￿ the small companies rcgime.
This report was approved by the Board of Directors Ènd Th￿tteS on 9 May 2023 and signed on its
bel￿1[ by:
Professor Ian Lauder

Ir+fTERNATIONAL JOURNAL OF EXPERIMENTAL PATHoL￿y
Independent examlner's report to the Tn￿ of knternational Journal of Experimental
PatlKdo
I retrf)rt to the ckwity Erustres on my examination of the ￿CoUnts of the chariiabl¢ company for the year
ended 31 [kcem1￿ 2(Y22 whith are sei ol￿ on pages 8 ￿ 13.
Rtspotisibilities Ind b&sis d ftp)rt
As the chariiy's ol the company (aod also direci¢)rs lor the purFK>ses of company law) you are
sponsible for the prepararion of the accounts in aca)rdw with the req￿Irements of the Companies Act
Having ￿eTr satisfied that the accounls of the cornpaDy are required audi*d under Part 16 of the
2(Xkn Act and are eligible for in(kpendem examina110￿ I in respeth of my exarnination of your
chaniy's accounls as caxrial out under seaion 145 of the Charities Aci 2011 ('the 2011 Act,). In canying out
my examination I hav¢ followed Directions given by the Charity Comttllssion unthr sedion 14515) Ib)
VI
Illde￿¢ eX￿nineT'S St4temeu¢
I have compkted my examination. I c(M)fum rAO matws have come io my wkntion in eonne£tion with
the examinatson giving tne cawe io Etlieve:
(11 accounting ffc(ffds were kept in ￿SP￿t of company as required by ￿11(￿ 386 of the 2(M
(21 the ac¢ouDts do n(* ac¢(*d with those rec￿&$. or
(3) the accounts do not comply with the accouniing rquirenKnts of section 196 of the 21Mkn Act {￿er
than any requirerneDt that th¢ a￿(￿￿$1$ give a. and fair view which is not a matter crnsidefftl as
pakl uf dii ithk"p¢iia¢iii ¢knliiiiatithi.
(4) the accounis have not been prepared in accord*Ke with a￿1 principles of the Sthtement
of Recommenlkd Prartice f(( accounting a￿] re￿rtIng by chariiies applicable to charitscs p￿Paring
their accounls in acc(Kdartt with the Fina￿la1 Re￿nIng Sthndard aP￿}cable in the UK and
Republic of Irela￿1 (FRS 102).
I have no concerns and hav¢ come xross w (rther matters ID C(XU￿tIOn with the examin￿On to which
r¢ach¢d.
Paul HWTIS
. Hantb & Llilli￿43
Chartered CtrtifKd Accountants
59 West End
Redruth
Cornwalj
9 May 2023

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Page 8
Statement of finsncial activities for the year ended 31 December 2022
Income and expenditure account
Notes
2022
2021
Income from:
Charitable activitie5
35,438
33,624
Invesiments
44,611
35,713
Total income
80.049
69.337
Expenditure on:
Charitable activities:
Research fellowship grants and prizes
Govemance costs
33,782
12,061
4,700
11,507
Total expenditure
45.843
16.207
Net income before inveslment (loss)Igain
34,206
53,130
Net (loss)Igain on investments
io
(175,123) 134,958
Net movement In funds
(140.917) 188,088
Reconciliation offunds:
Total funds brought forward
1.459,666 1.271,578
Total funds c8Thied forward
1,318.749 1.459.666
The notes on pages 10 to 13 forni part of these fitwicial stazements.

Page 9
2022
Fixed assets
lavestsnents
1.049.914
1,221.687
Current #sscts
tkbtors
IDvesthwits
Cash at bank
49.162
75.(
240.634
49.282
258.474
364.796
387.756
within one year
95,961
2.933
Net cuTr￿t &8sets
268.835
294.823
1.318,749
1516.510
Creditors: amouw falling due
after one year
Net assets
1318,749
1.459.666
FuNts of the clwity
1,119.243
1995
1,082.148
377J18
Fair value resetV¢
Total funds
io
1.318.749
1,459,666
The company was entided to exemption from audit under sKti(￿ 477 of the Companies Act 2006
re￿Ing to SU￿1] ¢onwies.
The members have not required the Colly￿y to obtsin an audit of its xcounts in accord￿ with
section 476 of the Companies Act 21K￿.
The directsn a¢knowledg¢ their responsibiliti&s for complying with the requiLEments of thc
These accounts have t*en pttpaTrd in with the PrnViSiODS applicable to small
conv￿ subjed to the small companies regill￿ and in tKcordance with FRS 102 SORP.
ved by the Boanl of Directs￿ a￿1 Tntstees on 9 May 2Q23 and signed on its Ixhalf.
Professor Ian Lauder
Director and Thtstee
The notes on pages 10 to 13 forni part of t1￿ finwKial slateiiwifs.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Page 10
Notes to the accounts for the year eDded 31 December 2022
Accounting policies
B&sis of accounting
The accounts have been prepared under the historical cost convention, with items recognised
at cost or transaction value. unless otherwis¢ sta(ed in the notes to these accounts.
The accounts have been prepared in accordance with the Ststement of Recommended
Practice: Accounting and Reporting by Charities prepariThg their accounts in accordance with
the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) -
(Charities SORP FRS 102) October 2019. the Financial Reporting Siandard applicable in che
UK and Republic of Ireland (FRS 102). the Charities Aci 2011 and the Companies Aci 2006.
The company meeis the definition of a public benefit enuty under FRS 102.
Income
Recognition of income:
These are included in the statement of financial activities (SOFA) when the ciwity becomes
entitled to the resources, it is more likely Ihan not that the Trnstees will receive the resources
and the monetary value can be me&sured with sufficient reliability.
Income from the Journal:
This is the company's Share of profit from the publication of the JournaI as shown in the
accounts produced by tlle Publisbei and is recognised when the charity has entitlemeni io the
funds.
tnvestment income:
This is included in the accounts wben receipi is probable and the amount receivable can be
measured reliably.
Investment gains and losses".
This includes any realised or unrealised gains or losses on the sale of investments and any
gain or loss resulting fiotn revaluing investments to markei value at the end of the year.
Expendithre and liabilities
Liability recognition-
Liabilities are recognised when it is more likely tban not that there is a legal or construciive
obligation committing the charity to pay out resources and the amount of the obligation can be
measured with reasonable certainry.
Governance and support costs:
Support costs have been allocated ￿tween governance and other support.
Govemance costs comprise all costs involving public accountability of the Charity and its
compliance with regulauon and good praccice.
Support costs include central funciions and are allocated io activiry cost categories on a basis
consisteni with the use of resources.
Grants payable without Ferformance conditions:
Where there are no performance conditions attsching to the grant payable. that enables the
cbari(y to realistically avoid the commitmenL a liability for the full funding obligation is
recognised.

LwfERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Page 11
Notes to the financial statements for the year ended 31 December 2022 (continued)
Accounting policies (contlnued)
Creditots..
Creditors are measured at settlement amounts. Value Added T&x is not recoverable by the
cllarity. and as such is included in the relevani costs.
Assets
Invest￿ents:
Fixed asset investments in quoted shares, traded bonds and similar investmenis are valued
initially at cost and subsequently at fait value (their market value) at the year end.
Debtors:
Debtors are measured on initial recognition ai settlement amount. Subsequently. they are
measured at the cash or other consi(kration expected to be received.
Current &sset iThvestments.'
The charity has cash deposits with a maturity of less than one year, held for investmenl
purposes rather than io meet shon term cash cotnmitm¢nts as they fall due.
Income from charitable activities
Income from charitable aciiviiies represents the company's share of profil from the publication
of the Journal, as shown in the accounts produced by the Publisher. after deducting non
rechargeable Editorial costs.
The current publishing agreement imposes a maximum annual limit on Editorial costs
incurred by the company that can be charged to the Publisher. In return, the company receives
a guaranteed profEt share ¢quivalent to 80% of the profit share paid to the company for the
previous year.
2022
2021
Share of profit
Editorial costs not recharged
37.639
(2.201)
36,751
(3,127)
35,438
33,624
Income from investments
2022
2021
Dividends from investment portfolio
Inleiest on bank deposits
42.575
2.036
34.518
1,195
44,611
35,713

INTERNATIONAL JOURNAL OF EXPERIMETrrfAL PATHOLOGY
Page 12
Notes to the Ilnancial Statements for the year ended 31 December 2022 (continued)
Research fellowship grants and prizes
2022
2021
Institutional grants:
Fellowship for MB PhD studies:
University College London
Institutional pri7£s and lectures:
British Society for Matrix Biology
Fell Muir award and travel costs
Rani Rawji Studeniships
27,882
800
3,000
33,782
4,7(M)
GoverDaDce costs
2022
2021
Fee for independent examiner
Other governance costs
9(K)
10,607
11.161
12.061
11.507
The Trustres received no remunerntion or reimbu￿ed expenses in 2022 and 2021. There are
no employees.
Invesknent &ssets
Fixed asset investments
Market value at l January 2022
Additions at cost
Disposals at marker value
1,221,687
21,165
(19,756)
1.223.096
{173.182)
Decrease in matket value for the year
Market value at 31 December 2￿22
1,049.914
The historical cost of lis*d InveStn￿Trts is £850.41Y) (2021 £844,170)
Current asset investments
2022
2021
C&sh deposits with a maturity of less Ehan one year
75.(KK)
80,000

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Page 13
Not￿ to the financial slatements for the year ended 31 December 2022 (eontlnued)
Debtors
2(Y22
2021
Trade debtors
Other debtors
47,705
1.457
47.715
1,567
49,162
49,282
Creditors: amounts falling due
within one year
2022
2021
Ac¢￿al$
95,961
92,933
Creditors: amounts falling due
after more than One year
2022
2021
Accrual for Fellowships awarded
56,844
10. Movement in funds
General Fair valu¢
Fund
reserve
Tot
Funds
At l January 2022
Net income for the year
Realised and unrealised loss on investments
Trdnsfer of surplus relating to investmenLS sold
1,082.148 377.518 1,459,666
34.2(
34,206
(1.941) (173,182) (175.123)
4,830
(4,830)
At 31 Decetnber 2022
1.119,243 199,506 1,318.749